Evidence from clinical trials showed the drug almost halves the rate of hearing loss in children receiving cisplatin chemotherapy
Children undergoing cancer treatment in...
Earlier this month, Aurobindo Pharma’s filgrastim biosimilar Zefylti achieved a positive opinion from EMA's CHMP
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has...
Patients treated with sugemalimab lived on average 9.0 months without disease progression, compared to 4.9 months in the placebo group
The Medicines and Healthcare products...